Gemini shares surge 25% on $100M Bitcoin infusion from Winklevoss Capital

Winklevoss Capital Fund injected $100 million into Gemini, using Bitcoin as collateral, sending the company’s shares up 25% to $14 per share in pre-market trading. The investment comes as Gemini reported a first-quarter 2026 net loss of $109 million, though revenue grew 42% year-over-year to $50.3 million. Operating expenses surged 73% to $144.5 million, driven by compensation, severance, and marketing costs, while trading volume fell 27% to $17.2 million despite a 17% rise in monthly transacting users. The infusion provides critical liquidity, as Gemini’s cash position stood at $215.6 million at quarter-end, down from $252.2 million. The company has been restructuring aggressively, cutting 25% of its workforce and exiting the UK, EU, and Australia to focus on high-potential areas like derivatives trading and fintech products. A CFTC-approved Derivatives Clearing Organization license positions Gemini to enter regulated derivatives markets, targeting institutional revenue streams. Despite the strategic shift, Gemini’s stock has plummeted 82% since its September 2025 IPO, when shares were priced at $28. The company now faces a securities class action lawsuit, adding legal pressure to its financial challenges. The $100 million investment, priced nearly triple the pre-announcement trading price of $4.92, signals confidence from the Winklevoss twins, who have historically bet heavily on long-term crypto growth. Analysts question whether Gemini’s restructuring and expansion efforts can offset its $109 million quarterly losses. The company’s pivot to derivatives, AI-driven tools, and consumer finance aims to diversify revenue beyond volatile spot trading. However, the burn rate remains unsustainable without continued external funding, leaving investors to weigh the risks of further losses against the potential of a broader fintech transformation.